GUJARAT THEMIS BIOSYN : JAPAN STEP-DOWN SUBSIDIARY ACQUIRES 100% EQUITY SHAREHOLDING OF MICROBIOPHARM JAPAN

• Gujarat Themis Biosyn's wholly owned subsidiary, Themis Biosyn Japan Limited, has completed the acquisition of 100% equity shareholding in MicroBiopharm Japan Co., Ltd. (MBJ), Japan. • The acquisition was made for a total consideration of JPY 21.5 billion, funded through an optimal mix of debt and equity. • MBJ operates three GMP-compliant manufacturing plants with a strong FDA and PMDA inspection track record and had revenue of JPY 9.5 billion in FY26. • The acquisition is expected to be EPS accretive for Gujarat Themis Biosyn Limited. • Gujarat Themis Biosyn Limited has also entered into a loan agreement with Themis Biosyn Japan Limited for an amount up to ₹800 Crores.

Gujarat Themis Biosyn Ltd

Open attachment

← Back to feed